FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or...

FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose...

For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a...

BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration...

Food and Drug Administration (FDA) approved a new medication called Journavx (suzetrigine) to treat moderate to severe acute pain in adults. This...

U.S. federal officials have approved a new pain pill aimed at preventing addiction and overdose risks linked to opioids like Vicodin and OxyContin....

FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.

FDA approves Journavx (suzetrigine), a new opioid designed to reduce addiction and overdose risks.

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.